Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Alrosa to auction a yellow brilliant weighing more than 30 carats

11/8/23 ALRS

Warner Bros.Discovery reported for 9 months of 2023

11/8/23 WBD

Biogen reported for 9 months of 2023

11/8/23 BIIB

Yakovlev will conduct an additional issue of 32 billion shares

11/8/23 IRKT

Samaraenergo reported for 9 months of 2023 by RAS

11/8/23 SAGO

Vladimir Chemical Plant reported for 9 months of 2023 by RAS

11/8/23 VLHZ

Henderson's LFL sales were up 26%

11/8/23 HNFG

LESK reported for 9 months of 2023 by RAS

11/8/23 LPSB

Ozon fears changes in state regulation of marketplaces

11/8/23 OZON

Sberbank will create a cross-bank bioacquiring platform

11/8/23 SBER